The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.

The CDC published a new recommendation this week calling for some adults ages 50 to 59 to get vaccinated for respiratory syncytial virus (RSV).

GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in at-risk adults aged 50 to 59.

RSV vaccine access expanded to some people in their 50s, according to CDC website The decision appears on a CDC webpage but wasn’t on the agency’s official adult immunization schedule.

ZBD enables Lightning-powered Bitcoin payments in SaruTobi, marking Apple’s first approval of Bitcoin microtransactions in an iOS game—a breakthrough driven by EU regulation and the aftermath of Epic ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following the advice of a recently fired panel of government vaccine advisers.

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60. Health Secretary Robert F. Kennedy Jr. recently fired the government vaccine ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60. Health Secretary Robert F. Kennedy Jr. recently fired the government vaccine ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following the advice of a recently fired panel of government vaccine advisers. The… ...

RSV vaccine access expanded to some people in their 50s, according to CDC website The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna's mRESVIA and Pfizer's Abrysvo. RSV is a ...